Recent studies indicate that dual inhibition of DNMTs and EZH2 exhibits synergistic antineoplastic activity against human myeloid leukemia cells [30], and can resensitize the resistant myeloma cells to both lenalidomide and pomalidomide in vitro [31]. Here, EZH2 is linked to plasma cell myeloma.